Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab plus glucocorticoid taper in polymyalgia rheumatica
jRCT2061230010Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in polymyalgia rheumatica (PMR) (3 arms), sponsored by Novartis. Primary endpoint: Sustained remission at Week 52. Started May 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on jRCT2061230010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230010.